NYSE: DOCSDoximity Inc Stock
$53.72+0.51 (+0.96%)
Updated Jan 17, 2025
DOCS Price
$53.72
Fair Value Price
N/A
Market Cap
$10.03B
52 Week Low
$22.96
52 Week High
$61.75
P/E
57.15x
P/B
10.43x
P/S
15.7x
PEG
13.78x
Dividend Yield
N/A
Revenue
$516.85M
Earnings
$174.11M
Gross Margin
89.9%
Operating Margin
43.79%
Profit Margin
33.7%
Debt to Equity
0.16
Operating Cash Flow
$224M
Beta
1.6
Next Earnings
Feb 6, 2025
Ex-Dividend
N/A
Next Dividend
N/A
DOCS Overview
Doximity. Inc. is an online networking service enabling medical professionals to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers. Formerly known as 3MD Communications, Inc., the company was launched in 2010 and is headquartered in San Francisco, CA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine DOCS's potential to beat the market
BBuy
- Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More
Zen Rating Component Grades
C
Value
C
Growth
C
Momentum
B
Sentiment
C
Safety
A
Financials
C
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Health Information Service
Industry Rating
C
DOCS
Ranked#8 of 51
Ranked#8 of 51
Be the first to know about important DOCS news, forecast changes, insider trades & much more!
DOCS News
Overview
Due Diligence Score
–
Industry Average (25)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how DOCS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
DOCS ($53.72) is trading above its intrinsic value of $6.25, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
DOCS is poor value based on its earnings relative to its share price (57.15x), compared to the US market average (30.45x)
P/E vs Market Valuation
DOCS is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more DOCS due diligence checks available for Premium users.
Valuation
DOCS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
57.15x
Industry
21.02x
Market
30.45x
DOCS is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
DOCS is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
DOCS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
10.43x
Industry
3.79x
DOCS is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
DOCS price to earnings growth (PEG)
For valuing profitable companies with growth potential
DOCS is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
DOCS's financial health
Profit margin
Revenue
$136.8M
Net Income
$44.2M
Profit Margin
32.3%
DOCS's Earnings (EBIT) of $226.33M... subscribe to Premium to read more.
Interest Coverage Financials
DOCS's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.1B
Liabilities
$157.3M
Debt to equity
0.16
DOCS's short-term assets ($957.71M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
DOCS's short-term assets ($957.71M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
DOCS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$68.3M
Investing
$24.2M
Financing
-$19.7M
DOCS's operating cash flow ($223.59M)... subscribe to Premium to read more.
Debt Coverage Financials
DOCS vs Health Information Service Stocks
Doximity Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.